TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04107142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Description: Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
Study: NCT05797584

Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine
Description: Dobutamine 5.0 - 10.0 mcg/Kg/min ev

Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raising
Description: Passive leg raising for acute volume load
Study: NCT03922074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation directed by an endoscopist
Description: The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation directed by an anesthesiologist
Description: The choice of the drugs and the target level sedation are directed by an anesthesiologist
Study: NCT01360866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Controlled-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Delayed-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Extended-release capsules
Study: NCT03380390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL 1.0% Cream
Description: Oxymetazoline HCl cream 1.0% once daily application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-Based Therapy
Description: Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
Study: NCT03615495

Intervention type: DEVICE
Intervention: Flourish Pediatric Esphogeal Atresia device
Description: The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
Study: NCT00870207

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tu Salud Si Cuenta Worksite Intervention
Description: The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tu Salud Si Cuenta Worksite Intervention
Description: The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
Study: NCT03393078

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation with real coil
Description: TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation with sham coil
Description: TMS with sham coil is a placebo
Study: NCT02951013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive transfusion
Description: Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liberal transfusion
Study: NCT01243619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-(18) F-fluorothymidine
Description: Radio-tracer for tumor imaging
Study: NCT03529396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Standard chloroquine (three days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Standard chloroquine (three days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Standard chloroquine (three days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Standard chloroquine (three days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
Study: NCT01684397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT03475368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbs diet
Description: People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: People randomized to this interventional group will take a traditional Mediterranean diet.
Study: NCT01684397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00828932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Study: NCT02671305

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental circulation intact
Description: bedside assistance with placental circulation intact during first 3 minutes of life

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cord milking
Description: neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
Study: NCT02040493

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative radiation therapy (IORT)
Description: All subjects will receive IORT at the time of lumpectomy.
Study: NCT02200432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSPeCT Recommender System
Description: PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient.
Study: NCT02415439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBP15

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00904540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (\>12 months LBP)
Study: NCT01604304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexible ureteroscopy
Description: Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
Study: NCT00550524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
Study: NCT01935791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle
Description: Temperature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon
Description: Hormone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative
Description: Temperature

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control
Description: Hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control
Description: Hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon
Description: hormone
Study: NCT01604304

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave lithotripsy
Description: The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
Study: NCT00200252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Study: NCT03480607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group
Description: 0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone group
Description: 0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
Study: NCT03164226

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
Description: To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
Study: NCT01935791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control
Description: hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control
Description: hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon
Description: Hormone
Study: NCT03513328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa--single daily dose
Description: Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa--single daily dose
Description: Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa--escalated dose
Description: Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa--escalated dose
Description: Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Study: NCT01924000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil lotion 1%
Description: Minoxidil lotion 1% is applied twice daily to one eyebrow.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04692025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 tablet
Description: Oral tablet
Study: NCT02538081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone plus Placebo
Description: Standard of care including Risperidone plus Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone plus DMXB-A
Description: Standard of care including Risperidone plus DMXB-A
Study: NCT01458236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium 314d Modified Release Tablets
Description: Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
Study: NCT02398578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphora OAB Device
Description: Cystoscopic procedure to treat OAB
Study: NCT01805804

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/valsartan
Study: NCT00804284

Intervention type: BIOLOGICAL
Intervention: DTaP-IPV/Hib
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Intervention: Other DTap Vaccines
Description: 0.5 mL, Intramuscular
Study: NCT02737696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based prescription opioid prevention for adolescents
Description: The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JustThinkTwice.gov website (DEA)
Description: The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
Study: NCT04584450

Intervention type: OTHER
Intervention: Questionnaire
Description: data collection using questionnaire
Study: NCT04169399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
Study: NCT01834703

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UAE
Description: The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HIFU
Description: Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
Study: NCT03148496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biologic Mesh
Description: Biologic mesh placed during surgery
Study: NCT02312817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Outreach Invitation
Description: Individuals randomized to Group 2 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailed Outreach Invitation and Patient Navigation
Description: Individuals randomized to Group 3 will receive:~1. Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~2. Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~3. Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic.
Study: NCT03408652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
Study: NCT04155710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-2001
Description: Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-2001
Description: Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-2001
Description: Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-2001
Description: Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2
Description: 6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose IL-2
Description: 6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 6 doses of IL-2 will follow the infusion of IOV-2001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 6 doses of IL-2 will follow the infusion of IOV-2001
Study: NCT03050671

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression, Rapid
Description: Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Pneumatic Compression, Slow
Description: Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way